ReviewCancers2024

Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials.

Ilaria Attili et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.